Tessa Ostyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tessa Ostyn has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Emilie Crouchet
University of Strasbourg, Inserm, UMR_S1110, Institute of Translational Medicine and Liver Disease (ITM), 67000 Strasbourg, France
2 shared publications- Fabio Del Zompo
University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France
2 shared publications Julien Moehlin
University of Strasbourg, Inserm, UMR_S1110, Institute of Translational Medicine and Liver Disease (ITM), 67000 Strasbourg, France
2 shared publications- Mélissa Messé
University of Strasbourg, Inserm, UMR_S1110, Institute of Translational Medicine and Liver Disease (ITM), 67000 Strasbourg, France
2 shared publications - Natascha Roehlen
Uniklinik Freiburg, Germany
2 shared publications - Olivier Govaere
Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven and University Hospitals Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in JHEP Reports
- p. 102064
Hippo signaling drives mesenchymal cell fate and heterogeneity in liver cancer
- 15 October 2026
- Published by Elsevier in JHEP Reports
- p. 102064
Open AccessHippo signaling drives mesenchymal cell fate and heterogeneity in liver cancer
- 3 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (852) , eadp2595
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models
Cholangiocarcinoma (CCA) is an adenocarcinoma of the hepatobiliary system that has recently risen in incidence and mortality with unsatisfactory treatment options. Claudin-1 (CLDN1) is a transmembrane protein expressed in tight junctions and exposed on the cell surface in liver fibrosis and cancer. Using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of tissues of patients with CCA, we show that CLDN1 expression is up-regulated in cancer cells and is associated with stemness and cell fate. Genetic gain-of-function studies in CCA orthotopic in vivo mouse models showed decreased survival and enhanced tumor growth, unraveling a functional role of CLDN1 as an oncogenic driver. Targeting exposed nonjunctional CLDN1 using highly specific CLDN1 monoclonal antibodies (mAbs) inhibited tumor growth across CCA CDX and PDX mouse models and patient-derived CCA organoids, including tumors with medium or low CLDN1 expression. Moreover, antibody treatment inhibited tumor cell migration, invasion, and extrahepatic metastasis. Mechanistically, targeting exposed cell surface CLDN1 on CCA tumors using mAbs inhibited Notch1 and TROP2/STAT3 signaling pathways, resulting in decreased cancer cell stemness and epithelial-to-mesenchymal transition. Loss-of-function studies using CRISPR-Cas9 and RNAi combined with rescue and confocal imaging studies confirmed the functional and mechanistic role of these pathways. In conclusion, these results uncover CLDN1 as a previously undiscovered CCA driver and therapeutic target, paving the way for the clinical development of CLDN1 mAbs to improve the dismal outcome of patients with advanced CCA.
- 3 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (852) , eadp2595
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models
Cholangiocarcinoma (CCA) is an adenocarcinoma of the hepatobiliary system that has recently risen in incidence and mortality with unsatisfactory treatment options. Claudin-1 (CLDN1) is a transmembrane protein expressed in tight junctions and exposed on the cell surface in liver fibrosis and cancer. Using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of tissues of patients with CCA, we show that CLDN1 expression is up-regulated in cancer cells and is associated with stemness and cell fate. Genetic gain-of-function studies in CCA orthotopic in vivo mouse models showed decreased survival and enhanced tumor growth, unraveling a functional role of CLDN1 as an oncogenic driver. Targeting exposed nonjunctional CLDN1 using highly specific CLDN1 monoclonal antibodies (mAbs) inhibited tumor growth across CCA CDX and PDX mouse models and patient-derived CCA organoids, including tumors with medium or low CLDN1 expression. Moreover, antibody treatment inhibited tumor cell migration, invasion, and extrahepatic metastasis. Mechanistically, targeting exposed cell surface CLDN1 on CCA tumors using mAbs inhibited Notch1 and TROP2/STAT3 signaling pathways, resulting in decreased cancer cell stemness and epithelial-to-mesenchymal transition. Loss-of-function studies using CRISPR-Cas9 and RNAi combined with rescue and confocal imaging studies confirmed the functional and mechanistic role of these pathways. In conclusion, these results uncover CLDN1 as a previously undiscovered CCA driver and therapeutic target, paving the way for the clinical development of CLDN1 mAbs to improve the dismal outcome of patients with advanced CCA.
- 20 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 449-462
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
- 20 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (3) , 449-462
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis
- Open Access
- 20 August 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1305-1319
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis
- 20 August 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (6) , 1305-1319
Open AccessClaudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis